FOXO Technologies Inc. announced plans for a new subscription-based, direct-to-consumer product offering that will provide personalized health and wellness recommendations, by combining: (i) FOXO's machine learning models to analyze epigenetic biomarkers; (ii) the Company's expertise and algorithms correlating epigenetic analysis with health outcomes; and (iii) published, peer-reviewed, clinical data and other verified, third-party health resources. In connection with the new offering, the Company also announced it has formed a collaboration with KR8.ai Inc. ("KR8") and secured an exclusive license to KR8's AI-based software to support the development and commercial launch of the new health and wellness offering.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
0.262 USD | +0.77% | +9.74% | -18.61% |
1st Jan change | Capi. | |
---|---|---|
-18.61% | 2.91M | |
-13.14% | 191B | |
+3.71% | 167B | |
+4.95% | 158B | |
+1.96% | 97.42B | |
+52.43% | 92.57B | |
+17.59% | 84.74B | |
+1.97% | 76.34B | |
-0.76% | 46.78B | |
-33.77% | 43.24B |
- Stock Market
- Equities
- FOXO Stock
- News FOXO Technologies Inc.
- FOXO Technologies Inc. Unveils Plans for New Direct-To Consumer Offering Combining the Company's Epigenetic Data with the Power of Ai